BOSTON SCIENTIFIC CORP

20 February, 2025

Boston Scientific Achieves Strong Buy Rating as Shares Surge 60% Amid Positive Earnings Outlook and Robust Market Position

Boston Scientific (BSX) continues to make strides in the medical devices sector, showcasing robust performance and investor enthusiasm. As of February 20, 2025, Boston Scientific holds a Zacks Rank of...
Read More

19 February, 2025

Boston Scientific Advances AFib Treatment with CE Mark Approval for Farapulse System and Sees Market Opportunities Amid Competitors' Challenges

Boston Scientific is making headlines in the medical technology sector with its Farapulse pulsed field ablation (PFA) system, which has recently garnered significant attention following both CE mark a...
Read More

18 February, 2025

Boston Scientific Reports Triple-Digit Growth and Market Leadership Through Farapulse PFA System Innovations in 2024

Boston Scientific has seen impressive growth in its electrophysiology portfolio, particularly following the success of its Farapulse pulsed field ablation (PFA) system. In Q4 2024, the company reporte...
Read More

15 February, 2025

Boston Scientific Surpasses Earnings Expectations with Strong Q4 2024 Performance, Reporting $4.56 Billion in Revenues and 70 Cents EPS

Boston Scientific reported impressive fourth-quarter results for 2024, showcasing its strong operational performance and growth potential. The company achieved adjusted earnings per share (EPS) of 70 ...
Read More